Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#11 / 198 Total
APLT - Applied Therapeutics Inc - Stock Price Chart
TickerAPLT [NASD]
CompanyApplied Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap535.79MEPS (ttm)-1.32
P/E-EPS this Y42.57%
Forward P/E-EPS next Y56.94%
PEG-EPS past 5Y-8.72%
P/S50.26EPS next 5Y-
P/B-EPS Q/Q-17.44%
Dividend-Sales Q/Q-
Insider Own22.09%Inst Own48.14%
Insider Trans-1.88%Inst Trans-5.87%
Short Float5.32%EarningsMay 09/b
Analyst Recom1.20Target Price11.60
Avg Volume1.78M52W Range1.18 - 9.39
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shendelman ShoshanaPresident and CEOMar 14 '24Sale5.39318,5731,717,1083,817,814Mar 18 06:12 PM
Perfetti RiccardoChief Medical OfficerMar 14 '24Sale5.39110,804597,2341,031,537Mar 18 06:02 PM
Hansard AdamChief Commercial OfficerMar 14 '24Sale5.3948,871263,415732,919Mar 18 06:00 PM
Funtleyder Leslie D.Chief Financial OfficerMar 14 '24Sale5.3928,727154,839308,421Mar 18 05:57 PM
Kanter Stacy J.DirectorDec 01 '23Buy2.1830,00065,36763,000Dec 05 07:03 PM
APYX - Apyx Medical Corp - Stock Price Chart
TickerAPYX [NASD]
CompanyApyx Medical Corp
CountryUSA
IndustryMedical Devices
Market Cap52.65MEPS (ttm)-0.54
P/E-EPS this Y-44.44%
Forward P/E-EPS next Y10.77%
PEG-EPS past 5Y-25.84%
P/S1.01EPS next 5Y15.00%
P/B1.97EPS Q/Q-58.64%
Dividend-Sales Q/Q16.26%
Insider Own17.97%Inst Own43.49%
Insider Trans0.85%Inst Trans-0.47%
Short Float1.31%EarningsMay 09/b
Analyst Recom1.80Target Price3.62
Avg Volume151.74K52W Range1.21 - 7.97
Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HILL MATTHEW CChief Financial OfficerDec 12 '23Buy2.192,5005,4752,500Dec 14 09:00 AM
Goodwin Charles D. IIChief Executive OfficerNov 14 '23Buy1.5750,00078,50090,000Nov 15 04:12 PM
Waldman LawrenceDirectorJul 12 '23Option Exercise2.975,33815,8545,338Jul 19 12:00 PM
Hornsby ToddExecutive Vice PresidentJun 26 '23Option Exercise1.7715,00026,55015,000Jun 28 02:01 PM
Hornsby ToddExecutive Vice PresidentJun 26 '23Sale7.5615,000113,40040Jun 28 02:01 PM
ARGX - Argen X SE ADR - Stock Price Chart
TickerARGX [NASD]
CompanyArgen X SE ADR
CountryNetherlands
IndustryBiotechnology
Market Cap22.66BEPS (ttm)-5.17
P/E-EPS this Y59.71%
Forward P/E96.08EPS next Y290.84%
PEG-EPS past 5Y-17.05%
P/S18.45EPS next 5Y-
P/B5.51EPS Q/Q10.02%
Dividend-Sales Q/Q82.26%
Insider Own0.63%Inst Own54.47%
Insider Trans0.00%Inst Trans-7.21%
Short Float2.25%EarningsMay 09/b
Analyst Recom1.48Target Price478.38
Avg Volume264.05K52W Range327.73 - 550.76
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
ARHS - Arhaus Inc - Stock Price Chart
TickerARHS [NASD]
CompanyArhaus Inc
CountryUSA
IndustryHome Improvement Retail
Market Cap2.18BEPS (ttm)0.89
P/E17.41EPS this Y-18.22%
Forward P/E17.62EPS next Y20.03%
PEG2.29EPS past 5Y81.22%
P/S1.70EPS next 5Y7.60%
P/B6.42EPS Q/Q-33.82%
Dividend-Sales Q/Q-3.46%
Insider Own64.03%Inst Own30.39%
Insider Trans-4.79%Inst Trans0.17%
Short Float9.45%EarningsMay 09/b
Analyst Recom1.36Target Price17.50
Avg Volume1.24M52W Range6.52 - 16.60
Arhaus, Inc. engages in the retail of furniture, outdoor, lighting, textiles, and decor. The company was founded by John Reed in 1986 and is headquartered in Hudson, OH.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sparks DawnChief Logistics OfficerMar 10 '24Option Exercise0.001,8720232,691Mar 12 04:54 PM
Porter Jennifer EChief Marketing OfficerMar 10 '24Option Exercise0.002,3400411,373Mar 12 04:55 PM
Chi LisaChief Merchandising OfficerMar 10 '24Option Exercise0.002,340071,219Mar 12 04:55 PM
Phillipson DawnChief Financial OfficerMar 10 '24Option Exercise0.002,3400650,331Mar 12 04:55 PM
VELTRI KATHY EChief Retail OfficerMar 10 '24Option Exercise0.002,3400381,204Mar 12 04:55 PM
ASLN - ASLAN Pharmaceuticals Ltd ADR - Stock Price Chart
TickerASLN [NASD]
CompanyASLAN Pharmaceuticals Ltd ADR
CountrySingapore
IndustryBiotechnology
Market Cap7.39MEPS (ttm)-2.75
P/E-EPS this Y31.41%
Forward P/E-EPS next Y-31.17%
PEG-EPS past 5Y17.51%
P/S0.62EPS next 5Y-
P/B-EPS Q/Q24.70%
Dividend-Sales Q/Q-
Insider Own3.48%Inst Own20.05%
Insider Trans0.00%Inst Trans-16.17%
Short Float1.47%EarningsMay 09/b
Analyst Recom1.00Target Price9.50
Avg Volume1.25M52W Range0.39 - 4.69
Today 07:00AM ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-24 07:30AM ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event (GlobeNewswire)
May-02-24 09:00AM ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics (GlobeNewswire)
Apr-30-24 07:00AM ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab (GlobeNewswire)
Apr-24-24 07:00AM ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference (GlobeNewswire)
Apr-22-24 08:45AM ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients (GlobeNewswire) -11.13%
Apr-19-24 05:10PM ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice (GlobeNewswire) -5.19%
Apr-12-24 08:00AM ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -7.37%
Apr-09-24 09:40AM Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year? (Zacks)
Mar-27-24 08:07AM Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders (GlobeNewswire)
Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which develops novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.
AURA - Aura Biosciences Inc - Stock Price Chart
TickerAURA [NASD, RUT]
CompanyAura Biosciences Inc
CountryUSA
IndustryBiotechnology
Market Cap373.92MEPS (ttm)-1.93
P/E-EPS this Y-3.90%
Forward P/E-EPS next Y-2.98%
PEG-EPS past 5Y-16.85%
P/S-EPS next 5Y-
P/B1.65EPS Q/Q4.19%
Dividend-Sales Q/Q-
Insider Own19.79%Inst Own72.03%
Insider Trans21.54%Inst Trans2.22%
Short Float6.51%EarningsMay 09/b
Analyst Recom1.00Target Price19.80
Avg Volume180.88K52W Range5.99 - 13.50
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de los Pinos ElisabetSee RemarksJan 23 '24Sale7.6415,853121,141161,438Jan 24 04:20 PM
Feder Julie BChief Financial OfficerJan 23 '24Sale7.646,60950,52162,991Jan 24 04:18 PM
Matrix Capital Management Comp10% OwnerNov 09 '23Buy9.001,560,00014,040,0006,922,870Nov 09 04:35 PM
Johnson David MichaelDirectorNov 08 '23Buy7.3020,000146,00075,000Nov 09 05:02 PM
Johnson David MichaelDirectorNov 08 '23Buy7.309,60170,087135,667Nov 09 05:02 PM
AUST - Austin Gold Corp - Stock Price Chart
TickerAUST [AMEX]
CompanyAustin Gold Corp
CountryCanada
IndustryGold
Market Cap13.09MEPS (ttm)-0.30
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.16EPS Q/Q-833.14%
Dividend-Sales Q/Q-
Insider Own50.11%Inst Own0.01%
Insider Trans0.00%Inst Trans-4.63%
Short Float0.66%EarningsMay 09/b
Analyst Recom1.00Target Price2.99
Avg Volume126.97K52W Range0.54 - 1.66
Austin Gold Corp. focuses on the acquisition, exploration and evaluation of mineral resource properties primarily in the western United States of America. Its projects includes Kelly Creek Project, Lone Mountain Project and Stockade Mountain Project. The company was founded on April 21, 2020 and is headquartered in Vancouver, Canada.
AVAH - Aveanna Healthcare Holdings Inc - Stock Price Chart
TickerAVAH [NASD, RUT]
CompanyAveanna Healthcare Holdings Inc
CountryUSA
IndustryMedical Care Facilities
Market Cap480.95MEPS (ttm)-0.71
P/E-EPS this Y23.86%
Forward P/E-EPS next Y77.19%
PEG-EPS past 5Y-22.80%
P/S0.25EPS next 5Y6.23%
P/B-EPS Q/Q89.45%
Dividend-Sales Q/Q6.14%
Insider Own29.25%Inst Own20.23%
Insider Trans0.00%Inst Trans-0.02%
Short Float0.77%EarningsMay 09/b
Analyst Recom3.25Target Price2.57
Avg Volume94.84K52W Range0.85 - 3.00
Aveanna Healthcare Holdings, Inc. engages in providing home care services to patients. It operates through the following business segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment includes private duty nursing services. The HHH segment provides home health, hospice, and program services to predominately elderly populations. The MS segment offers supplies to patients requiring enteral nutrition services or respiratory care. The company was founded on November 30, 2016 and is headquartered in Atlanta, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GANZI VICTOR FDirectorJun 06 '23Buy1.23200246236,617Jun 08 09:50 PM
GANZI VICTOR FDirectorJun 01 '23Buy1.183,2003,776236,417Jun 01 08:55 PM
GANZI VICTOR FDirectorMay 31 '23Buy1.1511,85013,616233,217Jun 01 08:55 PM
GANZI VICTOR FDirectorMay 30 '23Buy1.141,7582,008221,367Jun 01 08:55 PM
AVXL - Anavex Life Sciences Corporation - Stock Price Chart
TickerAVXL [NASD, RUT]
CompanyAnavex Life Sciences Corporation
CountryUSA
IndustryBiotechnology
Market Cap313.27MEPS (ttm)-0.54
P/E-EPS this Y20.00%
Forward P/E-EPS next Y-33.33%
PEG-EPS past 5Y-9.03%
P/S-EPS next 5Y-
P/B2.31EPS Q/Q36.90%
Dividend-Sales Q/Q-
Insider Own3.16%Inst Own30.65%
Insider Trans-2.75%Inst Trans-2.04%
Short Float27.68%EarningsMay 09/b
Analyst Recom1.00Target Price32.50
Avg Volume1.27M52W Range3.25 - 10.45
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MISSLING CHRISTOPHER UPresident and CEOMar 28 '24Option Exercise1.3273,38096,8621,323,590Apr 01 06:00 PM
MISSLING CHRISTOPHER UPresident and CEOMar 28 '24Sale5.1173,380374,9721,250,210Apr 01 06:00 PM
MISSLING CHRISTOPHER UPresident and CEOJun 29 '23Option Exercise1.60232,000371,2001,250,210Jun 30 08:00 PM
MISSLING CHRISTOPHER UPresident and CEOJun 28 '23Option Exercise1.60268,000428,8001,286,210Jun 30 08:00 PM
MISSLING CHRISTOPHER UPresident and CEOJun 28 '23Sale7.98268,0002,139,3101,018,210Jun 30 08:00 PM
AZUL - Azul S.A. ADR - Stock Price Chart
TickerAZUL [NYSE]
CompanyAzul S.A. ADR
CountryBrazil
IndustryAirlines
Market Cap694.53MEPS (ttm)-4.12
P/E-EPS this Y133.11%
Forward P/E4.53EPS next Y280.09%
PEG-EPS past 5Y-21.64%
P/S0.19EPS next 5Y-
P/B-EPS Q/Q-105.07%
Dividend-Sales Q/Q16.82%
Insider Own-Inst Own21.16%
Insider Trans-Inst Trans-0.94%
Short Float4.13%EarningsMay 09/b
Analyst Recom1.86Target Price13.18
Avg Volume1.65M52W Range5.16 - 13.86
Azul SA is a holding company, which engages in the provision of airline passenger and cargo services. The firm's service features include passenger seat selection, leather seats, individual entertainment screens with free live television at every seat in all E-Jets, extensive legroom with a pitch of 30 inches or more, complimentary beverage and snack services and free bus service to key airports. The company was founded by David Neeleman on January 03, 2008 and is headquartered in Barueri, Brazil.
12345671020